Research ExplorerPublicationsMolecular subgroups of medulloblastoma: the current consensu...

Molecular subgroups of medulloblastoma: the current consensus.

Standard

Molecular subgroups of medulloblastoma: the current consensus. / Taylor, Michael D; Northcott, Paul A; Korshunov, Andrey; Remke, Marc; Cho, Yoon-Jae; Clifford, Steven C; Eberhart, Charles G; Parsons, D Williams; Rutkowski, Stefan; Gajjar, Amar; Ellison, David W; Lichter, Peter; Gilbertson, Richard J; Pomeroy, Scott L; Kool, Marcel; Pfister, Stefan M.

In: ACTA NEUROPATHOL, Vol. 123, No. 4, 4, 2012, p. 465-472.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Taylor, MD, Northcott, PA, Korshunov, A, Remke, M, Cho, Y-J, Clifford, SC, Eberhart, CG, Parsons, DW, Rutkowski, S, Gajjar, A, Ellison, DW, Lichter, P, Gilbertson, RJ, Pomeroy, SL, Kool, M & Pfister, SM 2012, 'Molecular subgroups of medulloblastoma: the current consensus.', ACTA NEUROPATHOL, vol. 123, no. 4, 4, pp. 465-472. <http://www.ncbi.nlm.nih.gov/pubmed/22134537?dopt=Citation>

APA

Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., Ellison, D. W., Lichter, P., Gilbertson, R. J., Pomeroy, S. L., Kool, M., & Pfister, S. M. (2012). Molecular subgroups of medulloblastoma: the current consensus. ACTA NEUROPATHOL, 123(4), 465-472. [4]. http://www.ncbi.nlm.nih.gov/pubmed/22134537?dopt=Citation

Vancouver

Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y-J, Clifford SC et al. Molecular subgroups of medulloblastoma: the current consensus. ACTA NEUROPATHOL. 2012;123(4):465-472. 4.

Bibtex

@article{be0cee19be764d56af5ca0866ff9da99,
title = "Molecular subgroups of medulloblastoma: the current consensus.",
abstract = "Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.",
keywords = "Humans, Gene Expression Profiling, *Consensus, Transcriptome, *Cerebellar Neoplasms/classification/diagnosis/genetics, *Medulloblastoma/classification/diagnosis/genetics, Hedgehog Proteins, Wnt Proteins, Humans, Gene Expression Profiling, *Consensus, Transcriptome, *Cerebellar Neoplasms/classification/diagnosis/genetics, *Medulloblastoma/classification/diagnosis/genetics, Hedgehog Proteins, Wnt Proteins",
author = "Taylor, {Michael D} and Northcott, {Paul A} and Andrey Korshunov and Marc Remke and Yoon-Jae Cho and Clifford, {Steven C} and Eberhart, {Charles G} and Parsons, {D Williams} and Stefan Rutkowski and Amar Gajjar and Ellison, {David W} and Peter Lichter and Gilbertson, {Richard J} and Pomeroy, {Scott L} and Marcel Kool and Pfister, {Stefan M}",
year = "2012",
language = "English",
volume = "123",
pages = "465--472",
journal = "ACTA NEUROPATHOL",
issn = "0001-6322",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Molecular subgroups of medulloblastoma: the current consensus.

AU - Taylor, Michael D

AU - Northcott, Paul A

AU - Korshunov, Andrey

AU - Remke, Marc

AU - Cho, Yoon-Jae

AU - Clifford, Steven C

AU - Eberhart, Charles G

AU - Parsons, D Williams

AU - Rutkowski, Stefan

AU - Gajjar, Amar

AU - Ellison, David W

AU - Lichter, Peter

AU - Gilbertson, Richard J

AU - Pomeroy, Scott L

AU - Kool, Marcel

AU - Pfister, Stefan M

PY - 2012

Y1 - 2012

N2 - Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.

AB - Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.

KW - Humans

KW - Gene Expression Profiling

KW - Consensus

KW - Transcriptome

KW - Cerebellar Neoplasms/classification/diagnosis/genetics

KW - Medulloblastoma/classification/diagnosis/genetics

KW - Hedgehog Proteins

KW - Wnt Proteins

KW - Humans

KW - Gene Expression Profiling

KW - Consensus

KW - Transcriptome

KW - Cerebellar Neoplasms/classification/diagnosis/genetics

KW - Medulloblastoma/classification/diagnosis/genetics

KW - Hedgehog Proteins

KW - Wnt Proteins

M3 - SCORING: Journal article

VL - 123

SP - 465

EP - 472

JO - ACTA NEUROPATHOL

JF - ACTA NEUROPATHOL

SN - 0001-6322

IS - 4

M1 - 4

ER -